Please login to the form below

Not currently logged in
Email:
Password:

drisapersen

This page shows the latest drisapersen news and features for those working in and with pharma, biotech and healthcare.

CHMP backs two rare disease therapies at April meeting

CHMP backs two rare disease therapies at April meeting

The importance of Brineura to the company has gained prominence after it was forced to ditch Duchenne muscular dystrophy drug drisapersen in the face of regulatory resistance to approval.

Latest news

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Licence. 935. Prosensa / BioMarin. Drisapersen – for Duchenne muscular dystrophy.

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “early” approval. ... $20.31 before settling at around $19.00.  Prosensa has been busy since drisapersen failed a

  • Pharma deals during January 2014 Pharma deals during January 2014

    Terminations. Not surprisingly after the report of the failure of drisapersen in showing improvement in its phase III six minute walking study in Duchenne muscular dystophy, GSK announced the return of ... the drisapersen rights to Prosensa.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics